


Eldyenn Revenue
Biotechnology Research • San Diego, California, United States • 1-10 Employees
Eldyenn revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Key Contact at Eldyenn
Christian Dunk
CEO
Company overview
| Headquarters | San Diego, California, United States |
| NAICS | 541714 |
| Founded | 2023 |
| Employees | 1-10 |
About Eldyenn
Eldyenn is a revolutionary pre-commercial, late clinical-stage biotechnology start-up focused on being first to market with Low Dose Naltrexone (LDN) for the treatment of inflammatory diseases. Proven: Our research is backed by Dr. Jill Smith, a leading expert in the field. Safe: Low-dose naltrexone (LDN) has remarkably few side effects, most of which are minor. Effective: Clinically proven to reduce inflammation and disease flares. Completed Phase 2 trial has demonstrated LDN's exceptional safety and efficacy. Eldyenn will revolutionize how autoimmune diseases are managed, focusing on developing immunomodulatory – rather than immunosuppressive – drugs. We’re starting our journey with Low Dose Naltrexone (LDN). LDN works by regulating the immune system, unlike other drugs that suppress it. Furthermore, it has minimal side effects and can be administered orally, making it more convenient for patients. LDN could redefine the treatment pathways for autoimmune conditions and provide a much-needed solution for patients who are currently struggling to manage their symptoms.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Eldyenn has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Eldyenn has never raised funding before.
Frequently asked questions
4.8
40,000 users



